News and Press Releases
Press releases
Theralase® Demonstrates Unique Ability to Activate Rutherrin® with Diabetes Drug
Press Release, UncategorizedToronto, Ontario –August 21 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radi...
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Press Release, NMIBC, PCDs, PrivatePlacementJuly 8, 2024 - Theralase® is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement ("NBPP") offering ("Offering") of units ("Units")....
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Press Release, rutherrin, TSXV:TLTJune 20, 2024 - Theralase's, lead drug formulation, Rutherrin® was able to repurpose non-cancer drugs for cancer therapy in preclinical research....
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically
Press ReleaseJune 19, 2024 - Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model....
Rutherrin® Increases Efficacy of Immunotherapy Preclinically
Press ReleaseJune 18, 2024 - Rutherrin®, in preclinical research, has demonstrated an ability to increase the efficacy of immunotherapy....
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase®
Press ReleaseJune 14, 2024 - Reminder Notice of Annual General and Special Meeting on June 19, 2024 at 4:30 pm after the formal part of the meeting a virtual zoom presentation will follow at 5:30 pm...
Rutherrin® Increases Efficacy of Chemotherapy
Press ReleaseJune 12, 2024 - Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance....
Ruvidar Enhances Efficacy of Cancer Drug
Press ReleaseJune 10, 2024 - Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation....
Theralase® Successfully Destroys Lung Cancer
Press ReleaseJune 6, 2024 - Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”)....
Theralase® Technology Effective in Virus Inactivation
Press ReleaseJune 4, 2024 - Theralase's lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
